ORIGINAL RESEARCH article
Front. Endocrinol.
Sec. Thyroid Endocrinology
Volume 16 - 2025 | doi: 10.3389/fendo.2025.1659736
This article is part of the Research TopicLevothyroxine Therapy in Patients with Hypothyroidism: Volume IIView all 16 articles
CARDIOVASCULAR RISK AFTER TOTAL THYROIDECTOMY IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA UNDERGOING LEVOTHYROXINE REPLACEMENT MONOTHERAPY
Provisionally accepted- 1Department of Clinical Medicine and Surgery University of Naples, University of Naples Federico II, Naples, Naples, Italy
- 2Universita degli Studi di Napoli Federico II, Naples, Italy
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Prospective studies have demonstrated the favorable prognosis of differentiated thyroid cancer, primarily due to its low risk of recurrence and mortality. Considering these favorable outcomes, the most recent ATA guidelines recommend individualizing the degree of TSH suppression to balance the risks and benefits of LT4 therapy based on the aggressiveness of the disease. However, no studies have evaluated the cardiovascular risk in disease-free patients receiving long-term replacement doses of LT4 following the 2016 ATA guidelines. This study aimed to evaluate cardiovascular risk in disease-free athyreotic patients with differentiated thyroid cancer according to the 2021 European Society of Cardiology (ESC) guidelines. Only patients without major CV events prior to DTC diagnosis and treated with long-term LT4 therapy after the 2016 ATA guidelines were included. From a larger cohort, 300 disease-free patients who underwent total thyroidectomy—with or without radioiodine (RAI)—were selected and 102 patients were included in this study. The cardiovascular risk was assessed using the ESC 2021 scoring systems: SCORE2, SCORE2-OP, and SCORE2-Diabetes. Among the 102 patients analyzed in detail, 14 experienced major adverse cardiovascular events (MACE) over a mean follow-up of 12.79 ± 9.13 years post-DTC diagnosis. In patients without MACE, none were classified as having a very high CV risk. A high CV risk was observed in 6% (SCORE2), 38.5% (SCORE2-OP), and 50% (SCORE2-Diabetes) of patients. Moderate CV risk was found in 34% (SCORE2), 38.5% (SCORE2-OP), and 50% (SCORE2-Diabetes), while low risk was recorded in 60% (SCORE2) and 23% (SCORE2-OP). These findings highlight the need for careful cardiovascular monitoring during long-term follow-up in patients with differentiated thyroid cancer, even in the absence of overt disease.
Keywords: Levothyroxine, REAPLACEMENT THERAPY ,DIFFERENTIATED THYROID CANCER, cardiovascular risk, Thyroidectomized patients, MAJOR CATDIAC EVENTS
Received: 04 Jul 2025; Accepted: 04 Aug 2025.
Copyright: © 2025 Biondi, Martina, Calzolaio, Francesco, Iannotta, Gifuni, Ruberto, Crescenzo and Esposito. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bernadette Biondi, Department of Clinical Medicine and Surgery University of Naples, University of Naples Federico II, Naples, 80131, Naples, Italy
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.